middle.news
How Will Invion’s FDA Orphan Drug Win Transform Its Cancer Pipeline?
9:23am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
How Will Invion’s FDA Orphan Drug Win Transform Its Cancer Pipeline?
9:23am on Friday 31st of October, 2025 AEDT
Key Points
FDA grants Orphan Drug Designation for INV043 in anal cancer
Raised ~$1 million via Loyalty Entitlement Offer and $782K through convertible notes
Ongoing Phase I/II trials for non-melanoma skin cancer and planned anogenital cancer trial
New collaboration with Protect Animal Health to explore cancer treatments for pets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invion (ASX:IVX)
OPEN ARTICLE